Skip to navigation Skip to content



About this Medication
  • Brand Name: Ocrevus®
  • Chemical Name: ocrelizumab
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This medication is taken by intravenous (IV) infusion.


Ocrevus® is a humanized monoclonal antibody that targets CD20 positive B lymphocytes ( a type of white blood cell), which contribute to nerve damage in MS. 

Ocrevus is approved by the FDA for the treatment relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).

Click to read the Prescribing Information for healthcare professionals.
Click to read the Medication Guide for patients.



Financial Assistance Program

Genentech® Access Solutions

What You Need to Know About Ocrevus™

This video was created in Summer 2017 and features Derrick Robertson, MD, Janice Maldonado, MD and Kathleen Costello, MSCN. Information is accurate as of then. Please visit for the most updated information.


Your input is important!

We believe that people affected by MS live better lives when they're connected.  To help us provide you with the best resources, support and information, please provide your feedback in a short survey.
Take the survey